Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics

Nicole Créau1

  • 1Unité de Biologie Fonctionnelle et Adaptative, Sorbonne Paris Cité, Universite Paris Diderot, EAC4413 CNRS, 75205 Paris Cedex 13, France. creau@univ-paris-diderot.fr

Neural Plasticity
|August 1, 2012
PubMed

Insights

Mouse models are advancing Down syndrome research by revealing molecular and cellular changes in the brain. This helps understand genetic alterations and potential therapeutic targets for Down syndrome phenotypes.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Background:

  • Down syndrome, caused by trisomy 21, presents complex challenges in molecular and cellular research.
  • Understanding the molecular basis of Down syndrome phenotypes is crucial for developing targeted therapies.

Purpose of the Study:

  • To review recent molecular and cellular findings in Down syndrome mouse models.
  • To connect these findings to the characteristic phenotypes of Down syndrome.

Main Methods:

  • Characterization of brain alterations in established mouse models of Down syndrome.
  • Analysis of molecular and cellular data from these models.

Main Results:

  • Recent studies in mouse models have elucidated key molecular and cellular brain alterations.
  • These alterations provide insights into the pathogenesis of Down syndrome.

Conclusions:

  • Down syndrome mouse models are valuable tools for dissecting the molecular underpinnings of the condition.
  • Further research using these models can guide the development of strategies to ameliorate Down syndrome phenotypes.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Karyotyping01:17

Karyotyping

Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Meiosis I01:49

Meiosis I

Meiosis is a carefully orchestrated set of cell divisions, the goal of which—in humans—is to produce haploid sperm or eggs, each containing half the number of chromosomes present in somatic cells elsewhere in the body. Meiosis I is the first such division, and involves several key steps, among them: condensation of replicated chromosomes in diploid cells; the pairing of homologous chromosomes and their exchange of information; and finally, the separation of homologous chromosomes by a...
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.